Safety, Efficacy, and Central Nervous System Control in Patients with High Baseline Risk Factors Treated with Tarlatamab for SCLC or Extrapulmonary Small Cell Carcinoma.
Saved in:
| Title: | Safety, Efficacy, and Central Nervous System Control in Patients with High Baseline Risk Factors Treated with Tarlatamab for SCLC or Extrapulmonary Small Cell Carcinoma. |
|---|---|
| Authors: | Mullangi S; University of Kansas Medical Center, Kansas City, Kansas., Lekkala MR; The University of Kansas Cancer Center, Kansas City, Kansas., Blocker S; The University of Kansas Cancer Center, Kansas City, Kansas., Kim D; The University of Kansas Cancer Center, Kansas City, Kansas., Zhang J; The University of Kansas Cancer Center, Kansas City, Kansas., Huang C; The University of Kansas Cancer Center, Kansas City, Kansas., Neupane P; The University of Kansas Cancer Center, Kansas City, Kansas., Li H; The University of Kansas Cancer Center, Kansas City, Kansas., Schieber T; The University of Kansas Cancer Center, Kansas City, Kansas. |
| Source: | JTO clinical and research reports [JTO Clin Res Rep] 2025 Jul 03; Vol. 6 (11), pp. 100875. Date of Electronic Publication: 2025 Jul 03 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101769967 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-3643 (Electronic) Linking ISSN: 26663643 NLM ISO Abbreviation: JTO Clin Res Rep Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
